ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2020
Prevalence and predictors of cannabis use among men receiving androgen-deprivation therapy for advanced prostate cancer.
Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Prevalence, reasons for use, perceived benefits, and awareness of health risks of cannabis use among cancer survivors - implications for policy and interventions.Journal of cancer survivorship : research and practice · 2025Article
- A Scoping Review of Observational Research on Cannabis Use for Symptom Management in HIV and Cancer: Implications for Cannabis Nursing.Journal of clinical nursing · 2025Article
- Alcohol and Cannabis Use Associated with Cardiometabolic Biomarkers among "All of Us" Cancer Survivors.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Symptom trajectories over time by cannabis use status among patients undergoing cancer treatment.Scientific reports · 2024Article
- Cannabis and cancer: unveiling the potential of a green ally in breast, colorectal, and prostate cancer.Journal of cannabis research · 2024Review
- Perceptions and engagement of patients with chronic conditions on the use of medical cannabis: a scoping review.European journal of medical research · 2024Article
- Article
- Cannabinoid consumption among cancer patients receiving systemic anti-cancer treatment in the Netherlands.Journal of cancer research and clinical oncology · 2023Article
- Impacts of medical and non-medical cannabis on the health of older adults: Findings from a scoping review of the literature.PloS one · 2023Article
- The perceptions and beliefs of cannabis use among Canadian genitourinary cancer patients.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- Use of cannabis in urological cancer patients: A review to evaluate risk for cancer development, therapeutic use, and symptom management.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021Review
- Wonder or evil?: Multifaceted health hazards and health benefits ofSaudi journal of biological sciences · 2021Review
- Cannabis use among cancer survivors in the United States: Analysis of a nationally representative sample.Cancer · 2021Article
- Slovenian Pet Owners' Experience, Attitudes, and Predictors Regarding Cannabinoid Use in Dogs and Cats.Frontiers in veterinary science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionProstate cancer patients receiving androgen-deprivation therapy (ADT) often experience a combination of disease symptoms and treatment side effects. The therapeutic use of cannabis to alleviate these side effects has not been studied, despite increasing patient interest. With the increasing availability of cannabis, it is important for clinicians to understand the prevalence, predictors, and perceived benefits of cannabis use among patients with prostate cancer.
methodsA total of 222 men undergoing ADT were assessed in this two-part study. In part one, the cannabis-use questionnaire was administered to 56 men, probing demographics, usage habits, perspectives, and degrees of symptom relief related to cannabis use. In part two, 191 cryopreserved urine samples were retrieved and analyzed for the presence of tetrahydrocannabidiol (THC) metabolite 11-nor-Δ9-THC-COOH. The respondents were then stratified into two groups, users vs. non-users, and statistical analyses were conducted.
resultsQuestionnaire data revealed that 23.2% of surveyed men had recently used cannabis. In contrast, 5.8% of men had detectable levels of THC metabolite in their urine. Combined questionnaire and urine data revealed that cannabis users were significantly younger (p=0.003) and had lower testosterone levels (p=0.003) than non-users. The majority of men experiencing common ADT side effects reported some degree of relief following cannabis use.
conclusionsCannabis use among men with advanced prostate cancer receiving ADT is more prevalent than in the general population and the majority of other oncological cohorts. Lower testosterone levels and reported therapeutic benefit among cannabis users warrants confirmation in appropriate clinical trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.